文献速递鼻科

MP-AzeFlu可快速有效控制变应性鼻炎:丹麦一项非干预性研究结果

MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-01-19

该多中心、前瞻性、非干预性研究纳入170例≥12岁中重度变应性鼻炎患者,处方MP-AzeFlu(氮卓斯汀联合丙酸氟替卡松鼻喷剂)后使用视觉模拟量表(VAS)评估。VAS均值从基线67.1±19.3 mm降至最后一天28.4±23.7 mm,降低38.8±27.3 mm;第3天85.6%患者认为症状部分或良好控制。结论认为MP-AzeFlu在丹麦真实临床实践中提供有效、快速且持续的症状控制。

要点

  • MP-AzeFlu使VAS均值从基线67.1±19.3 mm降至最后一天28.4±23.7 mm,降低38.8±27.3 mm。
  • 第3天85.6%患者认为症状部分或良好控制。
  • 第1、3、7天及最后一天达到≤38 mm良好控制VAS阈值的患者比例分别为28.2%、44.2%、61.6%、71.4%。

核心结论

  • MP-AzeFlu在丹麦真实临床实践中为变应性鼻炎患者提供有效、快速且持续的症状控制,结果与欧盟及ARIA目标一致,并支持MP-AzeFlu在真实生活中治疗变应性鼻炎的有效性。

研究设计与样本

  • 多中心、前瞻性、非干预性研究,纳入170例(≥12岁)按ARIA定义的中重度变应性鼻炎患者,处方MP-AzeFlu。

主要发现

  • MP-AzeFlu使VAS均值从基线67.1±19.3 mm降至最后一天28.4±23.7 mm,降低38.8±27.3 mm。
  • 第3天85.6%患者认为症状部分或良好控制。
  • 疗效在不同疾病严重程度、表型(季节性、常年性或混合性变应性鼻炎)和患者年龄间保持一致。
  • 第1、3、7天及最后一天达到≤38 mm良好控制VAS阈值的患者比例分别为28.2%、44.2%、61.6%、71.4%。

关键数值与推荐

  • VAS评分范围0至100 mm,于第0、1、3、7天及约14天MP-AzeFlu使用后评估。
  • 第3天患者将疾病评估为良好控制、部分控制或未控制。
  • 良好控制VAS阈值为≤38 mm。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR) control is a priority in the European Union (EU), and Allergic Rhinitis and its Impact on Asthma (ARIA) has endorsed a visual analogue scale (VAS) as the new language of AR control. This study evaluated the effectiveness of MP-AzeFlu (Dymista®, antihistamine [azelastine], and intranasal corticosteroid [fluticasone propionate]) using a VAS in real-life clinical practice in Denmark. METHODS: The multicenter, prospective, non-interventional study included 170 patients (≥12 years) with ARIA-defined moderate-to-severe AR prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS (0 to 100 mm) on days 0, 1, 3, and 7 and after ∼14 days of MP-AzeFlu use. On day 3, patients assessed their disease as well controlled, partly controlled, or uncontrolled. Proportions of patients achieving VAS score cutoffs (well-controlled, partly controlled) were also calculated. RESULTS: MP-AzeFlu reduced mean ± standard deviation VAS score from 67.1 ± 19.3 mm at baseline to 28.4 ± 23.7 mm on the last day, a reduction of 38.8 ± 27.3 mm. At day 3, 85.6% of patients considered their symptoms to be partly or well controlled. Effectiveness was consistent across disease severity, phenotype (seasonal, perennial, or combined AR), and patient age. Respectively, 28.2%, 44.2%, 61.6%, and 71.4% of patients achieved ≤38 mm well-controlled VAS score cutoff on days 1, 3, and 7, and the last day. CONCLUSION: MP-AzeFlu provided effective, rapid, and sustained symptom control in a real-life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP-AzeFlu for the treatment of AR in real life.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Haahr PA, Jacobsen C, Christensen ME, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol. 2019. PMID: 30659752. doi:10.1002/alr.22258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。